Future oncology最新文献_第5页

RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC. RELAY: ramucirumab联合厄洛替尼治疗转移性egfr突变的日本老年NSCLC患者的安全性和有效性。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-25 DOI: 10.1080/14796694.2025.2560225

Kazumi Nishino, Takashi Seto, Makoto Nishio, Kazuto Nishio, Kazuo Kasahara, Miyako Satouchi, Kiyotaka Yoh, Hidetoshi Hayashi, Sotaro Enatsu, Tomoko Matsui, Sunoj Chacko Varughese, Carla Visseren-Grul, Kazuhiko Nakagawa

{"title":"RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.","authors":"Kazumi Nishino, Takashi Seto, Makoto Nishio, Kazuto Nishio, Kazuo Kasahara, Miyako Satouchi, Kiyotaka Yoh, Hidetoshi Hayashi, Sotaro Enatsu, Tomoko Matsui, Sunoj Chacko Varughese, Carla Visseren-Grul, Kazuhiko Nakagawa","doi":"10.1080/14796694.2025.2560225","DOIUrl":"10.1080/14796694.2025.2560225","url":null,"abstract":"Aim: The global phase III RELAY trial demonstrated the efficacy of ramucirumab (RAM) plus erlotinib (ERL) in patients with untreated metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). We present safety and efficacy profiles of RAM+ERL in Japanese elderly (aged ≥ 75 years) patients in RELAY.Methods: Patients were randomized (1:1) to RAM (10 mg/kg) or placebo (PL) intravenously every 2 weeks plus 150 mg/day ERL orally. Primary endpoint was progression-free survival (reported elsewhere). This report describes response rates, study drug exposure, dose adjustments, safety, and post-study treatment discontinuation therapies in Japanese elderly patients (RAM+ERL, n = 12; PL+ERL, n = 17).Results: Overall response rate was similar in RAM+ERL (83.3%) and PL+ERL (82.4%) arms. Median treatment duration of RAM and ERL was 6.0 and 15.4 months, respectively. Most patients had RAM and/or ERL dose adjustments. Adverse events, including grade ≥ 3 events, were similar in both treatment arms, although proteinuria occurred exclusively in the RAM+ERL arm (six patients; no grade ≥ 3 events). All patients received subsequent therapy after first-line study treatment; various subsequent therapies were used.Conclusion: These results suggest that RAM+ERL may be a suitable first-line treatment option for elderly patients with EGFR-mutated NSCLC.Clinical trial registration: www.clinicaltrials.gov identifier is NCT02411448.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3197-3206"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12520095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The modified-Gustave Roussy immune score: assessing immune prognosis in advanced gastric cancer patients at baseline. 改良的gustave Roussy免疫评分：评估晚期胃癌患者基线免疫预后。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-30 DOI: 10.1080/14796694.2025.2564062

Yue Ma, Yuting Pan, Yue Li, Guanghai Dai

{"title":"The modified-Gustave Roussy immune score: assessing immune prognosis in advanced gastric cancer patients at baseline.","authors":"Yue Ma, Yuting Pan, Yue Li, Guanghai Dai","doi":"10.1080/14796694.2025.2564062","DOIUrl":"10.1080/14796694.2025.2564062","url":null,"abstract":"Background: This retrospective study focused on patients with advanced gastric cancer (AGC) for whom traditional chemotherapy has limited efficacy and responses to immune checkpoint inhibitors (ICI) vary. It explored biomarkers for predicting immunotherapy response, with a particular focus on the modified Gustave Roussy immune score (mGRIm-s).Methods: The retrospective study enrolled 268 patients with stage IV gastric cancer who initiated ICI treatment at the PLA General Hospital between December 2014 and May 2021. Patients were stratified into low-risk and high-risk groups based on three risk factors: low albumin levels, high lactate dehydrogenase levels, and an elevated neutrophil-lymphocyte ratio.Results: The results showed that patients in the low mGRIm-s group had significantly longer progression-free survival (PFS) and overall survival (OS) compared to those in the high mGRIm-s group. Cox regression analysis identified high mGRIm-s as a significant risk factor for disease progression and mortality. Additionally, patients in the low mGRIm-s group demonstrated higher disease control rates in short-term efficacy assessments.Conclusion: This retrospective study provides new insights into the relationship between mGRIm-s and survival outcomes in AGC patients undergoing anti-PD-1 immunotherapy.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3305-3317"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: a propensity score-matched study. 程序性细胞死亡配体1 （PD-L1）抑制剂与程序性细胞死亡1 （PD-1）抑制剂用于广泛期小细胞肺癌的一线治疗：一项倾向评分匹配研究

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-29 DOI: 10.1080/14796694.2025.2562731

Zhuoran Sun, Yingfan Guo, Shuangqing Lu, Jiling Niu, Qinhao Xu, Hui Zhu, Yaru Tian

{"title":"Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: a propensity score-matched study.","authors":"Zhuoran Sun, Yingfan Guo, Shuangqing Lu, Jiling Niu, Qinhao Xu, Hui Zhu, Yaru Tian","doi":"10.1080/14796694.2025.2562731","DOIUrl":"10.1080/14796694.2025.2562731","url":null,"abstract":"Background: The clinical efficacy and safety differences between PD-L1 inhibitors and PD-1 inhibitors remain controversial for ES-SCLC. We conduct the retrospective study and propensity score-matched analysis to explore the potential differences between them.Methods: This retrospective study analyzed 736 ES-SCLC patients from three centers treated with EP plus either a PD-L1 or PD-1 inhibitor. According to PD-L1 or PD-1 inhibitors, they were divided into two groups. Propensity score matching (PSM, 1:1) was performed to balance the baseline characteristics of the two groups. The primary endpoints were OS and PFS.Results: As a result, 485 patients received PD-L1 inhibitors plus EP and 251 received PD-1 inhibitors plus EP. Before PSM, the PD-1 inhibitor group showed a significantly longer PFS (8.26 vs. 7.44 months; HR 1.252, p = 0.007), but no significant OS difference (20.30 vs. 18.85 months; p = 0.337). After PSM, both median OS (22.43 vs. 20.69 months) and PFS (8.23 months for both) were comparable, with no statistical differences (OS: HR 0.938, p = 0.613; PFS: HR 1.008, p = 0.940). Safety profiles were similar between groups.Conclusions: In conclusion, the overall efficacy and safety profile were similar between PD-L1 inhibitors and PD-1 inhibitors for the first-line treatment of ES-SCLC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3293-3304"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncologists' preferences for frontline TKI treatment of Ph+ acute lymphoblastic leukemia: a discrete choice experiment. 肿瘤学家对一线TKI治疗Ph+急性淋巴细胞白血病的偏好：离散选择实验。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-10-05 DOI: 10.1080/14796694.2025.2565497

Ajibade Ashaye, Natasha Ramachandran, Matthew Quaife, Yanyu Wu, Álvaro Alberto Gutiérrez-Vargas, Angelica Jiongco, Vamsi Kota, Bipin Savani, Caitlin Thomas

{"title":"Oncologists' preferences for frontline TKI treatment of Ph+ acute lymphoblastic leukemia: a discrete choice experiment.","authors":"Ajibade Ashaye, Natasha Ramachandran, Matthew Quaife, Yanyu Wu, Álvaro Alberto Gutiérrez-Vargas, Angelica Jiongco, Vamsi Kota, Bipin Savani, Caitlin Thomas","doi":"10.1080/14796694.2025.2565497","DOIUrl":"10.1080/14796694.2025.2565497","url":null,"abstract":"Aims: To evaluate hematologist-oncologists' preferences for frontline treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) using tyrosine kinase inhibitors (TKIs) + chemotherapy.Participants & methods: An online discrete choice experiment was conducted among US-based hematologist-oncologists. Participants viewed profiles of hypothetical TKI + chemotherapy treatments with varied levels of benefit and risks (minimal residual disease-negative complete remission [MRD-negative CR], arterial occlusive events, grade 3-4 hepatotoxicity, grade 3-4 hematotoxicity) and chose their recommended treatment for five patient profiles: \"less-complex\" baseline; age ≥ 65; ECOG score 3; diabetes; hypertension. Data were analyzed using mixed multinomial logit models.Results: 121 hematologist-oncologists participated. Increasing MRD-negative CR was most important to hematologist-oncologists, driving 65%-87% of decision-making across patient profiles. Relative importance of benefits/risks varied by patient profile. Pooled across patient profiles, hepatotoxicity was the most concerning risk, driving 14% of decision-making. Based on PhALLCON data and elicited preferences, hematologist-oncologists were predicted to select the profile of ponatinib + chemotherapy over imatinib + chemotherapy for all included patient profiles. Predicted probabilities of choosing ponatinib over imatinib ranged from 87%-98% across patient profiles.Conclusions: Hematologist-oncologists prioritized achieving MRD-negative CR when recommending frontline treatments for Ph+ ALL, accepting some risks if offset by meaningful improvement in MRD-negative CR.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3329-3342"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145232377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors. HERTHENA-PanTumor01: patritumab deruxtecan （HER3-DXd）在先前治疗的晚期实体瘤中的II期研究

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-10-14 DOI: 10.1080/14796694.2025.2561539

Thomas Powles, Aarti Bhatia, Barbara Burtness, Takahiro Kogawa, Tomohiro Nishina, Izuma Nakayama, Christos Fountzilas, Dani R Castillo, Meredith McKean, Funda Meric-Bernstam, Nicoletta Colombo, James W Smithy, Jérome Fayette, Sunandana Chandra, David W Sternberg, Fan Jin, Kendall Sullivan, Sue Yueh, Graham Clinthorne, Ariel E Aguilo, Ragini Kudchadkar, Hidetoshi Hayashi

{"title":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.","authors":"Thomas Powles, Aarti Bhatia, Barbara Burtness, Takahiro Kogawa, Tomohiro Nishina, Izuma Nakayama, Christos Fountzilas, Dani R Castillo, Meredith McKean, Funda Meric-Bernstam, Nicoletta Colombo, James W Smithy, Jérome Fayette, Sunandana Chandra, David W Sternberg, Fan Jin, Kendall Sullivan, Sue Yueh, Graham Clinthorne, Ariel E Aguilo, Ragini Kudchadkar, Hidetoshi Hayashi","doi":"10.1080/14796694.2025.2561539","DOIUrl":"10.1080/14796694.2025.2561539","url":null,"abstract":"Human epidermal growth factor receptor 3 (HER3) is a receptor tyrosine kinase that is expressed in numerous solid tumors. Higher levels of HER3 expression in multiple tumor types are associated with adverse clinical outcomes, such as reduced survival. However, there is currently no HER3-directed antibody-drug conjugate approved for the treatment of any cancer. Improved treatment options are needed, in particular for patients who progress on standard therapies. HER3-DXd is an investigational HER3-directed antibody-drug conjugate composed of an anti-HER3 monoclonal antibody linked to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. In previous clinical trials, HER3-DXd demonstrated a manageable safety profile and durable efficacy in previously treated, advanced EGFR-mutated NSCLC and advanced breast cancer across a range of baseline tumor HER3 expression levels. HER3-DXd has also shown preclinical antitumor efficacy in HER3-expressing cancers including cutaneous melanoma, gastric cancer, and prostate cancer, among others. The aim of this global phase II HERTHENA-PanTumor01 multicohort study is to assess the efficacy and safety of HER3-DXd in patients with relapsed or refractory locally advanced or metastatic solid tumors including melanoma, head and neck squamous cell, gastric/gastroesophageal junction, ovarian, cervical, endometrial, bladder, esophageal squamous cell, pancreatic, and prostate cancers.Clinical trial registration: NCT06172478 (ClinicalTrials.gov); 2023-507641-29-00 (EudraCT); jRCT2031230575 (Japan Registry of Clinical Trials).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3283-3292"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical outcomes of everolimus in patients with hormone receptor positive breast cancer: a real-world analysis. 依维莫司治疗激素受体阳性乳腺癌患者的临床结果：一项现实世界分析。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-29 DOI: 10.1080/14796694.2025.2567485

Xinyu Gui, Yuhong Liu, Ying Yan, Lijun Di, Guohong Song

{"title":"Clinical outcomes of everolimus in patients with hormone receptor positive breast cancer: a real-world analysis.","authors":"Xinyu Gui, Yuhong Liu, Ying Yan, Lijun Di, Guohong Song","doi":"10.1080/14796694.2025.2567485","DOIUrl":"https://doi.org/10.1080/14796694.2025.2567485","url":null,"abstract":"Aims: The study aimed to evaluate the effectiveness and safety of everolimus combined with endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.Methods: Data from adult patients with HR+/HER2- advanced breast cancer at Beijing Cancer Hospital between January 2012 and February 2025 were analyzed retrospectively.Results: A total of 137 patients were included and the median progression-free survival (PFS) was 4.13 months (95% confidence interval [CI]: 2.86-5.40). The objective response rate and disease control rate (DCR) were 10.9% and 51.1%, respectively. No significant difference was found in PFS between different lines of therapy (p = 0.433) or different combination drugs with everolimus (p = 0.528). The median PFS in patients without prior use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors was 4.20 months, compared to 3.07 months in patients previously treated with CDK4/6 inhibitors (p = 0.466). The patients with prior CDK4/6 inhibitors for more than six months exhibited an extended PFS when subsequently treated with everolimus plus endocrine therapy (7.63 vs. 2.03 months, p<0.001). Meanwhile, everolimus-based treatment was generally well-tolerated.Conclusion: For patients with HR+/HER2- advanced breast cancer, everolimus combined with endocrine therapy may serve as an alternative option after disease progression on CDK4/6 inhibitors.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-9"},"PeriodicalIF":2.6,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer. 利用凝血酶时间临床特征预测乳腺癌1-2个前哨淋巴结阳性状态下的非前哨淋巴结转移

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-29 DOI: 10.1080/14796694.2025.2565827

Gang Chen, Yuhan Bao, Yidan Wang, Jianqiao Cao, Chao Yu, Guangdong Qiao, Yizi Cong

{"title":"Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.","authors":"Gang Chen, Yuhan Bao, Yidan Wang, Jianqiao Cao, Chao Yu, Guangdong Qiao, Yizi Cong","doi":"10.1080/14796694.2025.2565827","DOIUrl":"10.1080/14796694.2025.2565827","url":null,"abstract":"Background: This study aims to investigate biomarkers for predicting non-SLN metastasis and tumor metastatic burden in patients with 1-2 positive sentinel lymph nodes (SLNs).Research design and methods: 581 patients with SLN metastasis were enrolled, and their blood biochemical indices and clinical information were tested and analyzed.Results: Among patients with 1-2 positive SLNs, the SLN positivity rate was higher in the non-SLN metastasis group than in the non-metastasis group. Additionally, thrombin time (TT) and fibrinogen (Fbg) levels were lower in the non-SLN metastasis group compared with the non-metastasis group, with ROC AUC = 0.712. Regarding tumor burden, among patients with 1-2 positive SLNs, the SLN positivity rate was significantly higher in those with metastasis lymph nodes (mLNs) ≥ 4 than in those with <4 mLNs, with ROC AUC = 0.727.Conclusions: The SLN positivity rate, TT, and Fbg may serve as potential biomarkers for non-SLN metastasis in patients with 1-2 positive SLNs. Additionally, the SLN positivity rate may serve as a potential biomarker for mLNs ≥ 4 in cases with 1-2 positive SLNs and in those with only 1 positive SLN.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":2.6,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Social media for healthcare professionals in oncology: results from a cross-sectional survey conducted across eight countries in Asia, Latin America, and the Middle East. 肿瘤学医疗保健专业人员的社交媒体：来自亚洲、拉丁美洲和中东八个国家的横断面调查结果。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-12 DOI: 10.1080/14796694.2025.2548192

Deborah Mukherji, Mohit Agarwal, Humaid O Al-Shamsi, Martin Angel, Diogo Augusto Rodrigues Da Rosa, Sewanti Limaye, Vikas Talreja, Waleed El Morsi, Yüksel Ürün, Enrique Grande

{"title":"Social media for healthcare professionals in oncology: results from a cross-sectional survey conducted across eight countries in Asia, Latin America, and the Middle East.","authors":"Deborah Mukherji, Mohit Agarwal, Humaid O Al-Shamsi, Martin Angel, Diogo Augusto Rodrigues Da Rosa, Sewanti Limaye, Vikas Talreja, Waleed El Morsi, Yüksel Ürün, Enrique Grande","doi":"10.1080/14796694.2025.2548192","DOIUrl":"https://doi.org/10.1080/14796694.2025.2548192","url":null,"abstract":"Aims: Guidance and regulation for the use of social media (SM) by healthcare professionals (HCPs) is lacking in some parts of the world. This paper explores the significance and barriers of SM in oncology care in regions beyond Europe and North America.Methods: A cross-sectional survey facilitated by Sermo to explore the use of SM among oncologists in Argentina, Brazil, India, Mexico, Saudi Arabia, Taiwan, Türkiye, and the United Arab Emirates was conducted between 14 June 2023 and 28 June 2023. A panel discussion involving seven digital opinion leaders (DOLs) was also held.Results: Of 340 respondents, the survey found strong support for SM in public and HCP education with most preferring mobile phones and 88% accessing SM in their free time. SM has an average-to-great impact on the prescribing habits of 52% of respondents. Sixty-four percent of respondents are concerned about potential conflicts of interest with SM. The panel developed a framework of recommendations providing navigational aids for key information, verifying sources to avoid misinformation, disclosing conflicts of interests, and creating visual and bite-sized content.Conclusion: Opportunities exist to enhance SM use in regions beyond Europe and North America. DOLs in oncology can enhance SM content quality.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-14"},"PeriodicalIF":2.6,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-12 DOI: 10.1080/14796694.2025.2560753

引用次数: 0

Patient characteristics, treatment patterns, and clinical outcomes in HER2-negative early breast cancer by germline BRCA status. her2阴性早期乳腺癌的患者特征、治疗模式和临床结果与种系BRCA状态有关。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-22 DOI: 10.1080/14796694.2025.2548163

Jay A Andersen, Jagadeswara Rao Earla, Nicole Fulcher, Juliet Ndukum, Nicholas Robert, Mark E Robson, Weiyan Li, Jaime Mejia

{"title":"Patient characteristics, treatment patterns, and clinical outcomes in HER2-negative early breast cancer by germline BRCA status.","authors":"Jay A Andersen, Jagadeswara Rao Earla, Nicole Fulcher, Juliet Ndukum, Nicholas Robert, Mark E Robson, Weiyan Li, Jaime Mejia","doi":"10.1080/14796694.2025.2548163","DOIUrl":"10.1080/14796694.2025.2548163","url":null,"abstract":"Introduction: This study evaluated treatment patterns and survival among patients receiving systemic therapy for HER2- early breast cancer (eBC).Methods: A retrospective observational cohort study was used to evaluate gBRCA testing rates; treatment patterns and survival between patients tested positive for gBRCA (gBRCAm) and randomly selected patients with wildtype BRCA (gBRCAwt).Results: gBRCA testing rate was 8.2%, and gBRCA mutated rate was 9.8%. Most hormone receptor-positive [HR+]/HER2- patients received adjuvant only treatment, while triple negative breast cancer [TNBC] patients commonly received neoadjuvant only treatment. Among HR+/HER2- patients, 60-month survival was numerically greater for gBRCAwt than gBRCAm. In TNBC patients, gBRCAm ware associated with numerically better invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) compared to gBRCAwt.Conclusions: The study survival outcomes among HER2- patients are not significantly different based on gBRCA mutation status, although gBRCAm status is associated with slightly poorer survival. Among patients with structured electronic health record data, the gBRCA testing rate was 8.2%, with a mutation rate of 9.8% among those tested. While these rates reflect under-documentation in electronic health records, they highlight the need for improved capture of genetic testing in real-world settings.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2835-2849"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0